Stem Cell-Derived Beta Cells
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About BioTalentum
BioTalentum is an established Hungarian SME operating at the intersection of regenerative medicine, in vitro toxicology, and contract research services. Its core business leverages induced pluripotent stem cell (iPSC) technology to create 2D and 3D human cell models for predictive drug testing and disease research, with a strong focus on neurobiology, cardiac tissue, and beta cells for diabetes. The company has a dual revenue model, combining scientific services and product sales with a significant consulting practice for EU-funded research projects, evidenced by a strong track record in FP6, FP7, H2020, and Horizon Europe programs. With nearly 20 years of operation, it is recognized as a national SME champion in EU funding.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |